Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.52 |
| ▸ | CNR2 | P34972 | 3/20 | 0.52 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CMA1 | P23946 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | AGXT | P21549 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5646550 | 0.90 | CNR2 (0.60) | CNR1CNR2KIF11ACHE | |
| SCHEMBL14025162 | 0.87 | CNR2 (0.68) | CNR1CNR2 | |
| SCHEMBL3435840 | 0.85 | KIF11 (0.46) | CNR1CNR2KIF11ACHECA1 | |
| SCHEMBL22096345 | 0.84 | CNR1 (0.48) | CNR1CNR2KIF11ACHECA1 | |
| SCHEMBL23057946 | 0.84 | TP53 (0.49) | CNR1CNR2ALDH1A1CYP3A4 | |
| SCHEMBL18737497 | 0.83 | KIF11 (0.47) | CNR1CNR2KIF11 | |
| SCHEMBL19455957 | 0.83 | KIF11 (0.42) | CNR1CNR2KIF11ACHECA1 | |
| SCHEMBL8705771 | 0.81 | KIF11 (0.46) | CNR1CNR2KIF11ACHECA1 | |
| SCHEMBL25968340 | 0.81 | CNR2 (0.55) | CNR1CNR2KIF11ACHECA1 | |
| SCHEMBL17129735 | 0.81 | ALDH1A1 (0.46) | CNR1CNR2CA1CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20210009549-A1 | CANNABINOID DERIVATIVES AND CONJUGATES AND USES THEREOF | BEETLEBUNG PHARMA LTD (IL) | 2021-01-14 | — | — | US | disclosed |
| WO-2019159168-A1 | CANNABINOID DERIVATIVES AND CONJUGATES AND USES THEREOF | BEETLEBUNG PHARMA LTD. (IL) | 2019-08-22 | — | — | WO | disclosed |
| US-7259266-B2 | Benzopyran compounds useful for treating inflammatory conditions | PHARMACIA CORPORATION (US) | 2007-08-21 | — | — | US | disclosed |
| EP-1631562-A1 | CHROMENE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | Pharmacia Corporation (US) | 2006-03-08 | — | — | EP | disclosed |
| EP-1615905-A2 | BENZOPYRAN COMPOUNDS USEFUL FOR TREATING INFLAMMATORY CONDITIONS | Pharmacia Corporation (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20050148627-A1 | Benzopyran compounds for use in the treatment and prevention of inflammation related conditions | CARTER JEFFERY (US) | 2005-07-07 | — | — | US | disclosed |
| US-20050148777-A1 | Benzopyran compounds useful for treating inflammatory conditions | CARTER JEFFERY (US) | 2005-07-07 | — | — | US | disclosed |
| WO-2004087687-A1 | CHROMENE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | PHARMACIA CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004087686-A2 | BENZOPYRAN COMPOUNDS USEFUL FOR TREATING INFLAMMATORY CONDITIONS | PHARMACIA CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148777-A1 | Benzopyran compounds useful for treating inflammatory conditions | PTGES2, PTGER2, PTGS2 | CNR1 71/4885CNR2 42/4885KIF11 4857/4885 |
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | SLC40A1, HAMP, SLC19A1 | CNR1 3903/4885CNR2 4121/4885KIF11 4616/4885 |
| US-20210009549-A1 | CANNABINOID DERIVATIVES AND CONJUGATES AND USES THEREOF | CNR1, GLRA1, GLRA3 | CNR1 1/4885CNR2 4/4885KIF11 3424/4885 |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | CNR1 3350/4885CNR2 3411/4885KIF11 3615/4885 |
| US-20050148627-A1 | Benzopyran compounds for use in the treatment and prevention of inflammation related conditions | PTGES2, PTGER2, PTGES | CNR1 95/4885CNR2 36/4885KIF11 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.